
Drs. Dahiya, Spiegel Discuss CAR-T Secondary Malignancies Risk
The HemOnc Pulse
Risk of Therapy-Related Myeloid Neoplasms in CAR-T Patients
Discussion on the concerns and complexities surrounding the development of secondary myeloid malignancies in patients undergoing CAR-T therapy, with emphasis on comparing incidence rates and potential factors influencing this risk.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.